Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Thoracic cancer - 1 Jul 2018

Kim Tae-Ok, Oh In-Jae, Kho Bo Gun, Park Ha Young, Chang Jin Sun, Park Cheol-Kyu, Shin Hong-Joon, Lim Jung-Hwan, Kwon Yong-Soo, Kim Yu-Il, Lim Sung-Chul, Kim Young-Chul, Choi Yoo-Duk

Abstract excerpt

BACKGROUND: In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer (NSCLC) patients in real-world clinical practice. METHODS: We retrospectively reviewed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease Progression

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 29761660
DOI: 10.1111/1759-7714.12762
PMCID: PMC6026616

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.PMID 29761660Read ↗

Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.Semantic proximity Read ↗

Observational Study of Re-Biopsy in EGFR-TKI-Resistant Patients with EGFR Mutation-Positive Advanced NSCLCSemantic proximity Read ↗

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).Semantic proximity Read ↗

Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.Semantic proximity Read ↗

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.Semantic proximity Read ↗

Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.Semantic proximity Read ↗

The Clinical Impact of Re-biopsies in Lung Adenocarcinoma: a Retrospective Multicenter Study.Semantic proximity Read ↗

Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy.Semantic proximity Read ↗

Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications.Semantic proximity Read ↗

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.Semantic proximity Read ↗

Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.